Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angus G Dalgleish

Showing results (81-90 of 83) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 83 results.
British Journal of Cancer|September 7, 2016
Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancerAngus G Dalgleish, Justin Stebbing, Douglas Ja Adamson, et al.
British Journal of Cancer|October 12, 2016
Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancerAngus G Dalgleish, Justin Stebbing, Douglas J A Adamson, et al.
Journal for Immunotherapy of Cancer|April 23, 2020
Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanomaJonathan S Cebon, Martin Gore, John F Thompson, et al.
Pageof 9

Showing results (81-90 of 83) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 83 results.
British Journal of Cancer|September 7, 2016
Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancerAngus G Dalgleish, Justin Stebbing, Douglas Ja Adamson, et al.
British Journal of Cancer|October 12, 2016
Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancerAngus G Dalgleish, Justin Stebbing, Douglas J A Adamson, et al.
Journal for Immunotherapy of Cancer|April 23, 2020
Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanomaJonathan S Cebon, Martin Gore, John F Thompson, et al.
Pageof 9